JRJosé Ramos-Castañeda

José Ramos-Castañeda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


José Ramos-Castañeda has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluation of dengue virus seroprevalence in four boroughs of Mexico City among persons aged 5-35 years in 2022

    by Eleazar Coba-Alcalá, Lilia Chihu-Amparán, Irma Yvonne Amaya-Larios, Susana Román-Pérez, Rene Santos-Luna, Lorena Suárez-Idueta, Sonia López-Álvarez, Cristal Morales-Trevizo, Jesús Felipe González-Roldán, Ruth Aralí Martínez-Vega, et al.

    Introduction: Dengue is currently the most widespread vector-borne disease, and its transmission has been intensively studied in endemic/hyperendemic localities. However, to obtain a complete picture of dengue transmission, it is necessary to study nonendemic localities. Imported dengue cases have been reported in Mexico City, and the presence of eggs of the vector Aedes aegypti has been detected. Methodology: In the present study, we determined the prevalence of IgG antibodies against Dengue virus in four city boroughs via random cluster sampling in individuals aged 5-35 years. Results: The weighted seroprevalence rate was 1.90% (95% CI 0.75-4.75) at Xochimilco, 1.81% (95% CI 0.64-5.00) at Venustiano Carranza, 1.81% (95% CI 0.54-5.83) at Tlahuac, and 5.48% (95% CI 1.96-14.43) at Gustavo A Madero; seropositivity was concentrated in the adult group, many of whom lived in dengue-endemic localities. The distribution of seroprevalence in the four boroughs is very homogeneous and unrelated to the number of vector eggs in the borough. Conclusions: These data suggest that there is still no autochthonous transmission of dengue in Mexico City. However, it is important to note that the structural conditions of the dwellings in these boroughs, which offer minimal barriers to vector infestation, could facilitate the establishment of local transmission under favorable conditions.


  • Open Access

    The Insulin Receptor Substrate 2 Mediates the Action of Insulin on HeLa Cell Migration via the PI3K/Akt Signaling Pathway

    by Anabel Martínez Báez, Ivone Castro Romero, Lilia Chihu Amparan, Jose Ramos Castañeda, Guadalupe Ayala

    Insulin signaling plays an important role in the development and progression of cancer since it is involved in proliferation and migration processes. It has been shown that the A isoform of the insulin receptor (IR-A) is often overexpressed, and its stimulation induces changes in the expression of the insulin receptor substrates (IRS-1 and IRS-2), which are expressed differently in the different types of cancer. We study the participation of the insulin substrates IRS-1 and IRS-2 in the insulin signaling pathway in response to insulin and their involvement in the proliferation and migration of the cervical cancer cell line. Our results showed that under basal conditions, the IR-A isoform was predominantly expressed. Stimulation of HeLa cells with 50 nM insulin led to the phosphorylation of IR-A, showing a statistically significant increase at 30 min (p ≤ 0.05). Stimulation of HeLa cells with insulin induces PI3K and AKT phosphorylation through the activation of IRS2, but not IRS1. While PI3K reached the highest level at 30 min after treatment (p ≤ 0.05), AKT had the highest levels from 15 min (p ≤ 0.05) and remained constant for 6 h. ERK1 and ERK2 expression was also observed, but only ERK2 was phosphorylated in a time-dependent manner, reaching a maximum peak 5 min after insulin stimulation. Although no effect on cell proliferation was observed, insulin stimulation of HeLa cells markedly promoted cell migration.


  • Combine dengue vaccines to optimize effectiveness

    by Alejandro Macias, Guillermo Ruiz-Palacios, Jose Ramos-Castaneda


  • Open Access

    When Can One Vaccinate with a Live Vaccine after Wild-Type Dengue Infection?

    by Bruno Guy, Eng Eong Ooi, Jose Ramos-Castañeda, Stephen J. Thomas

    Recommendations have been issued for vaccinating with the Sanofi Pasteur tetravalent dengue vaccine (CYD-TDV, Dengvaxia®) individuals aged from 9 to 45/60 years old with a prior dengue virus (DENV) infection and living in endemic countries/areas. One question linked to these recommendations is to determine when it is possible to start vaccination after laboratory confirmed wild-type DENV infection, and this question can be relevant to any live vaccine to be used in endemic areas. To address it, we reviewed and discussed the immunological and practical considerations of live vaccination in this context. Firstly, the nature and kinetics of immune responses triggered by primary or secondary DENV infection may positively or negatively impact subsequent live vaccine take and associated clinical benefit, depending on when vaccination is performed after infection. Secondly, regarding practical aspects, the “easiest” situation would correspond to a confirmed acute dengue fever, only requiring knowing when the patient should come back for vaccination. However, in most cases, it will not be possible to firmly establish the actual date of infection and vaccination may have to take place during well-defined periods, regardless of when prior infection occurred. Evidence that informs health authorities and medical practitioners in formulating vaccine policies and implementing vaccine programs is thus needed. The present work reviewed the different elements of the guidance and proposes some key conclusions and recommendations.


  • Open Access

    Seroprevalence of dengue in school children in Mexico ages 6–17 years, 2016

    by Irma Y Amaya-Larios, Mario Rojas-Russell, Malaquias López-Cervantes, Lilia Castro-Porras, Ma Victoria Castro-Borbonio, Elsa Sarti, Esteban Puentes-Rosas, Laura L Tirado-Gómez, Gustavo Olaíz-Fernandez, José Ramos-Castañeda

    Dengue is the most important arboviral disease in the world. Seroprevalence has been proposed as a marker of endemicity, however, studies are scarce. We conducted a cross-sectional, stratified cluster, random sample study to measure the seroprevalence of antibodies to dengue virus (DENV) in Mexico. The target population was school children ages 6–17 y from 22 endemic states in Mexico, clustered in four regions: Pacific, South-Central, Southeast and Low. A total of 2134 subjects provided blood samples for immunoglobulin G antibody detection in serum by enzyme-linked immunosorbent assay. Overall, the seroprevalence of antibodies against DENV was 33.5% (95% confidence interval [CI] 27.5 to 40.1). The Southeast had the highest regional seroprevalence, reaching 70.9% (95% CI 60.3 to 79.7). Seroprevalence was higher in older children in the Southeast region: 62.1% (95% CI 46.9 to 75.2) in children 6–8 y and 82.6% (95% CI 73.8 to 88.9) in 13–17 years old (y). However, this was not consistent in all regions. Seroprevalence was associated with dengue incidence. DENV seroprevalence in Mexico was found to be heterogeneous at the country, regional and state levels. Seroprevalence was linked to long-term exposure and did not adequately reflect recent patterns of transmission, suggesting that utilization of a single epidemiological indicator to define endemic regions should be avoided.